Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL776230 | 0.81 | CA1 (0.33) | CA1CA2CA7CA13 | |
| SCHEMBL19112362 | 0.78 | CA1 (0.31) | CA1CA2CA9 | |
| SCHEMBL776343 | 0.75 | — | — | |
| SCHEMBL11897837 | 0.75 | — | — | |
| SCHEMBL256378 | 0.75 | — | — | |
| SCHEMBL19958855 | 0.75 | CA1 (0.33) | CA1CA2CA7CA13 | |
| Fluoride SCHEMBL776344 | 0.73 | — | — | |
| SCHEMBL23934777 | 0.72 | CA1 (0.41) | CA1CA2CA7CA13 | |
| SCHEMBL777742 | 0.72 | CA1 (0.35) | CA1CA2CA7CA13CA9 | |
| SCHEMBL65750 | 0.72 | CA1 (0.41) | CA1CA2CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
| US-11492345-B2 | Compounds and their methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220149436-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11283107-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-03-22 | — | — | US | disclosed |
| US-20200247793-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20190229372-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-07-25 | — | — | US | disclosed |
| WO-2018148745-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES , INC. (US) | 2018-08-16 | — | — | WO | disclosed |
| CN-105531277-B | Pyrrolo-imidazole ring derivatives and their use in medicine | 四川海思科制药有限公司 | 2018-03-02 | — | — | CN | disclosed |
| US-9608291-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2017-03-28 | — | — | US | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| US-20120177988-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-07-12 | — | — | US | disclosed |
| US-20120070731-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2019825-B9 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INT (DE) | 2011-01-26 | — | — | EP | disclosed |
| US-7709481-B2 | Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-05-04 | — | — | US | disclosed |
| US-20090325065-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2012386-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-20080261979-A1 | Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247793-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CA1 285/4885CA2 213/4885CA7 1067/4885 |
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CA1 285/4885CA2 213/4885CA7 1067/4885 |
| US-11492345-B2 | Compounds and their methods of use | SCN1A, SCN3A, SCN1B | CA1 285/4885CA2 213/4885CA7 1067/4885 |
| US-20080261979-A1 | Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals | PPARD, PPARA, PPARG | CA1 4848/4885CA2 3443/4885CA7 4597/4885 |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK1 | CA1 4390/4885CA2 3251/4885CA7 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.